Cover Image
市場調查報告書

絲蟲病(淋巴系絲蟲症):開發平台分析

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302485
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
絲蟲病(淋巴系絲蟲症):開發平台分析 Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 32 Pages
簡介

絲蟲病(別名:淋巴系絲蟲症)是絲蟲寄生蟲透過蚊子傳播到人體而發病的傳染病。一般是在幼兒期感染,對淋巴系統造成隱性傷害。被分類為family Filariodidea的蛔蟲感染是造成該疾病的主要致病原因。主要症狀有朣脹、發冷顫抖、發汗、頭痛、嘔吐等。主要治療法為抗生素。

本報告提供全球各國治療絲蟲病(淋巴系絲蟲症)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

絲蟲病概要

治療藥的開發

  • 絲蟲病開發中產品:概要
  • 絲蟲病開發中產品:比較分析

各企業正在開發的絲蟲病治療藥

大學/研究機關研究中的絲蟲病治療藥

開發中產品的概要

  • 初期階段的產品

絲蟲病治療藥:開發中的產品一覽(各企業)

絲蟲病治療藥:研究中的產品一覽(大學/研究機關別)

絲蟲病開發治療藥的企業

  • Johnson & Johnson
  • Eisai
  • Anacor Pharmaceuticals, Inc.

絲蟲病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

  • 絲蟲症疫苗
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • flubendazole
  • IIC-942A001
  • IIC-950A001
  • 淋巴系絲蟲症小分子
  • S-0112091
  • S-0112094
  • 絲蟲病小分子
  • 淋巴系絲蟲症小分子
  • 淋巴系絲蟲症·線狀蟲病小分子
  • 線蟲病小分子

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8242IDB

Summary

Global Markets Direct's, 'Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2016', provides an overview of the Elephantiasis (Lymphatic Filariasis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis)
  • The report reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Elephantiasis (Lymphatic Filariasis) therapeutics and enlists all their major and minor projects
  • The report assesses Elephantiasis (Lymphatic Filariasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Elephantiasis (Lymphatic Filariasis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Elephantiasis (Lymphatic Filariasis) Overview
  • Therapeutics Development
    • Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Overview
    • Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics under Development by Companies
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics under Investigation by Universities/Institutes
  • Elephantiasis (Lymphatic Filariasis) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Elephantiasis (Lymphatic Filariasis) - Products under Development by Companies
  • Elephantiasis (Lymphatic Filariasis) - Products under Investigation by Universities/Institutes
  • Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
    • Eisai Co., Ltd.
    • Johnson & Johnson
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • EDE-1206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filariasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flubendazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IIC-950A001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lymphatic filariasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-0112091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lymphatic Filariasis and Onchocerciasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2016
  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co., Ltd., H2 2016
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Johnson & Johnson, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2016
  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top